Product News

Share this article:
The FDA has granted Caraco Pharmaceutical Laboratories approval for its Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Tablets indicated as short-term monotherapy for the management of exogenous obesity. According to IMS data, for the 12 months ended June 2007, Phentermine HCl generic and brand products (Adipex-P) combined had annual sales of approximately $34 million.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.